Symbols / XLO Stock $8.31 -1.89% Xilio Therapeutics, Inc.

Healthcare • Biotechnology • United States • NCM
XLO (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Biotechnology
CEO Dr. Rene Russo BCPS, Pharm.D.
Exch · Country NCM · United States
Market Cap 48.05M
Enterprise Value -81.60M
Income -35.04M
Sales 43.77M
FCF (ttm) 8.03M
Book/sh 7.79
Cash/sh 23.78
Employees 76
Insider 10d —
IPO Oct 22, 2021
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E —
Forward P/E -14.33
PEG —
P/S 1.10
P/B 1.07
P/C —
EV/EBITDA 2.02
EV/Sales -1.86
Quick Ratio 2.53
Current Ratio 2.58
Debt/Eq 19.71
LT Debt/Eq —
EPS (ttm) -4.19
EPS next Y -0.58
EPS Growth —
Revenue Growth 6.94%
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) 2025-11-13
Earnings (prior) 2025-11-13
ROA -23.25%
ROE -132.53%
ROIC —
Gross Margin 100.00%
Oper. Margin -86.48%
Profit Margin -80.05%
Shs Outstand 5.78M
Shs Float 3.45M
Insider Own 29.48%
Instit Own 35.40%
Short Float 3.97%
Short Ratio 3.80
Short Interest 182.49K
52W High 16.52
vs 52W High -49.70%
52W Low 6.47
vs 52W Low 28.48%
Beta -0.12
Impl. Vol. —
Rel Volume 0.88
Avg Volume 37.87K
Volume 33.29K
Target (mean) $20.00
Tgt Median $20.00
Tgt Low $20.00
Tgt High $20.00
# Analysts 1
Recom None
Prev Close $8.47
Price $8.31
Change -1.89%
About

Xilio Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of masked immuno-oncology therapies. The company's pipeline includes XTX501, a bispecific PD-1 / masked IL-2, for patients with metastatic non-small cell lung cancer; Efarindodekin alfa, an investigational, masked IL-12, that is in Phase 2 clinical trial for patients with advanced solid tumors; and Vilastobart, an investigational tumor-activated, Fc-enhanced, high affinity binding anti-CTLA-4 monoclonal antibody. The company was founded in 2016 and is headquartered in Waltham, Massachusetts.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$20.00
Mean price target
2. Current target
$8.31
Latest analyst target
3. DCF / Fair value
$24.99
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$8.31
Low
$20.00
High
$20.00
Mean
$20.00

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2025-08-06 init Leerink Partners — → Outperform $2
2024-11-08 main Raymond James Outperform → Outperform $4
2023-05-30 reit Chardan Capital Buy → Buy $7
2023-05-11 reit Chardan Capital — → Buy $7
2023-01-27 main Morgan Stanley — → Overweight $10
2022-12-21 init Chardan Capital — → Buy $7
2022-11-10 main Raymond James — → Outperform $13
2022-08-10 main Morgan Stanley — → Overweight $20
2022-01-10 init HC Wainwright & Co. — → Buy $36
2021-11-16 init Raymond James — → Outperform $31
2021-11-16 init Cowen & Co. — → Outperform —
2021-11-16 init Morgan Stanley — → Overweight $32
News
RSS: Latest XLO news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2026-01-02 BRENNAN KEVIN M Officer — 1,826 $0.64 $1,174
2026-01-02 FRANKENFIELD CHRISTOPHER JAMES Chief Financial Officer — 7,030 $0.64 $4,522
2025-12-31 RUSSO RENE PHARM.D. Chief Executive Officer — 44,250 — —
2025-12-31 BRENNAN KEVIN M Officer — 5,000 — —
2025-12-31 FRANKENFIELD CHRISTOPHER JAMES Chief Financial Officer — 19,375 — —
2025-12-31 LUPTAKOVA KATARINA M.D. Officer — 16,625 — —
2025-11-26 GILEAD SCIENCES INC Beneficial Owner of more than 10% of a Class of Security — 13,335,000 $0.75 $9,999,916
2025-06-17 SHANNON JAMES SAMUEL Director — 70,000 $0.69 $48,085
2025-06-16 RUSSO RENE PHARM.D. Chief Executive Officer — 36,289 $0.68 $24,680
2025-01-02 BRENNAN KEVIN M Officer — 1,803 $0.98 $1,774
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
43.77
+589.88%
6.34
0.00
0.00
Operating Revenue
43.77
+589.88%
6.34
0.00
0.00
Operating Expense
85.75
+29.94%
65.99
-16.61%
79.13
-11.24%
89.15
Research And Development
56.04
+35.98%
41.21
-20.95%
52.14
-11.93%
59.20
Selling General And Administration
29.71
+19.90%
24.78
-8.22%
27.00
-9.85%
29.95
General And Administrative Expense
29.71
+19.90%
24.78
-8.22%
27.00
-9.85%
29.95
Salaries And Wages
16.32
+11.44%
14.65
-7.46%
15.83
-5.23%
16.70
Other Gand A
13.39
+32.14%
10.13
-9.29%
11.17
-15.68%
13.25
Total Expenses
85.75
+29.94%
65.99
-16.61%
79.13
-11.24%
89.15
Operating Income
-41.98
+29.61%
-59.65
+24.63%
-79.13
+11.24%
-89.15
Total Operating Income As Reported
-41.98
+30.70%
-60.58
+23.44%
-79.13
+11.24%
-89.15
EBITDA
-40.44
+30.28%
-58.00
+24.90%
-77.23
+11.53%
-87.30
Normalized EBITDA
-46.29
+18.89%
-57.06
+26.11%
-77.23
+11.53%
-87.30
Reconciled Depreciation
1.54
-6.27%
1.64
-13.47%
1.90
+2.87%
1.85
EBIT
-41.98
+29.61%
-59.65
+24.63%
-79.13
+11.24%
-89.15
Total Unusual Items
5.84
+723.80%
-0.94
0.00
—
Total Unusual Items Excluding Goodwill
5.84
+723.80%
-0.94
0.00
—
Special Income Charges
0.00
+100.00%
-0.94
0.00
—
Restructuring And Mergern Acquisition
0.00
-100.00%
0.94
0.00
—
Net Income
-35.04
+39.84%
-58.24
+23.77%
-76.40
+13.40%
-88.22
Pretax Income
-35.04
+39.84%
-58.24
+23.77%
-76.40
+13.40%
-88.22
Other Income Expense
6.95
+394.73%
1.40
-48.55%
2.73
+194.39%
0.93
Other Non Operating Income Expenses
1.10
-52.97%
2.34
-14.22%
2.73
+194.39%
0.93
Gain On Sale Of Security
5.84
—
—
—
Tax Rate For Calcs
0.00
0.00
0.00
0.00
Tax Effect Of Unusual Items
0.00
0.00
0.00
0.00
Net Income Including Noncontrolling Interests
-35.04
+39.84%
-58.24
+23.77%
-76.40
+13.40%
-88.22
Net Income From Continuing Operation Net Minority Interest
-35.04
+39.84%
-58.24
+23.77%
-76.40
+13.40%
-88.22
Net Income From Continuing And Discontinued Operation
-35.04
+39.84%
-58.24
+23.77%
-76.40
+13.40%
-88.22
Net Income Continuous Operations
-35.04
+39.84%
-58.24
+23.77%
-76.40
+13.40%
-88.22
Normalized Income
-40.88
+28.66%
-57.30
+25.00%
-76.40
+13.40%
-88.22
Net Income Common Stockholders
-35.04
+39.84%
-58.24
+23.77%
-76.40
+13.40%
-88.22
Diluted EPS
-4.19
+72.54%
-15.26
+60.79%
-38.92
+13.66%
-45.08
Basic EPS
-4.19
+72.54%
-15.26
+60.79%
-38.92
+13.66%
-45.08
Basic Average Shares
8.36
+118.70%
3.82
+94.61%
1.96
+0.38%
1.96
Diluted Average Shares
8.36
+118.70%
3.82
+94.61%
1.96
+0.38%
1.96
Diluted NI Availto Com Stockholders
-35.04
+39.84%
-58.24
+23.77%
-76.40
+13.40%
-88.22
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Assets
154.69
+117.64%
71.08
+16.66%
60.93
-56.22%
139.16
Current Assets
145.03
+140.77%
60.23
+25.16%
48.13
-61.34%
124.50
Cash Cash Equivalents And Short Term Investments
137.53
+148.74%
55.29
+23.68%
44.70
-62.87%
120.39
Cash And Cash Equivalents
137.53
+148.74%
55.29
+23.68%
44.70
-62.87%
120.39
Receivables
5.00
0.00
—
—
Other Receivables
5.00
—
—
—
Prepaid Assets
—
—
—
4.11
Other Current Assets
2.50
-49.50%
4.94
+44.41%
3.42
-16.74%
4.11
Total Non Current Assets
9.66
-10.91%
10.84
-15.30%
12.80
-12.75%
14.67
Net PPE
7.85
-13.33%
9.06
-18.14%
11.07
-13.81%
12.84
Gross PPE
16.60
+0.72%
16.49
-2.61%
16.93
-1.91%
17.26
Accumulated Depreciation
-8.75
-17.85%
-7.43
-26.72%
-5.86
-32.66%
-4.42
Properties
0.00
0.00
0.00
0.00
Buildings And Improvements
—
4.59
-10.50%
5.12
—
Machinery Furniture Equipment
0.68
-21.18%
0.86
+0.00%
0.86
+0.00%
0.86
Construction In Progress
0.46
0.00
0.00
-100.00%
0.10
Other Properties
10.34
-1.51%
10.50
-4.04%
10.94
-2.08%
11.17
Leases
5.12
+0.00%
5.12
+0.00%
5.12
+0.00%
5.12
Other Non Current Assets
1.81
+1.40%
1.78
+2.89%
1.73
-5.30%
1.83
Total Liabilities Net Minority Interest
119.41
+123.30%
53.48
+121.91%
24.10
-28.10%
33.52
Current Liabilities
56.27
+106.42%
27.26
+70.84%
15.96
-24.44%
21.12
Payables And Accrued Expenses
9.17
+9.91%
8.35
+21.73%
6.86
-14.70%
8.04
Payables
3.17
+23.08%
2.57
+145.14%
1.05
-66.40%
3.12
Accounts Payable
3.17
+23.08%
2.57
+145.14%
1.05
-66.40%
3.12
Current Accrued Expenses
6.01
+4.04%
5.77
-0.59%
5.81
+18.17%
4.91
Pensionand Other Post Retirement Benefit Plans Current
5.73
+36.24%
4.21
-10.28%
4.69
-13.36%
5.41
Current Debt And Capital Lease Obligation
1.34
+13.05%
1.19
-72.76%
4.36
-42.49%
7.58
Current Debt
—
—
3.31
-50.28%
6.67
Other Current Borrowings
—
—
3.31
-50.28%
6.67
Current Capital Lease Obligation
1.34
+13.05%
1.19
+13.47%
1.05
+14.05%
0.92
Current Deferred Liabilities
40.02
+196.07%
13.52
0.00
—
Current Deferred Revenue
40.02
+196.07%
13.52
0.00
—
Other Current Liabilities
—
—
0.05
-41.46%
0.08
Total Non Current Liabilities Net Minority Interest
63.14
+140.84%
26.22
+221.98%
8.14
-34.33%
12.40
Long Term Debt And Capital Lease Obligation
5.61
-19.31%
6.95
-14.59%
8.14
-34.09%
12.35
Long Term Debt
—
—
—
3.17
Long Term Capital Lease Obligation
5.61
-19.31%
6.95
-14.59%
8.14
-11.39%
9.19
Non Current Deferred Liabilities
20.64
+7.13%
19.26
0.00
—
Non Current Deferred Revenue
20.64
+7.13%
19.26
0.00
—
Other Non Current Liabilities
7.33
—
—
0.04
Stockholders Equity
35.27
+100.44%
17.60
-52.21%
36.83
-65.14%
105.65
Common Stock Equity
35.27
+100.44%
17.60
-52.21%
36.83
-65.14%
105.65
Capital Stock
0.00
0.00
-100.00%
0.00
+0.00%
0.00
Common Stock
0.00
0.00
-100.00%
0.00
+0.00%
0.00
Preferred Stock
0.00
0.00
0.00
0.00
Share Issued
4.53
+38.62%
3.27
-88.16%
27.61
+0.66%
27.43
Ordinary Shares Number
4.53
+38.62%
3.27
-88.16%
27.61
+0.66%
27.43
Additional Paid In Capital
454.06
+13.13%
401.35
+10.77%
362.34
+2.14%
354.75
Retained Earnings
-418.79
-9.13%
-383.75
-17.89%
-325.51
-30.67%
-249.11
Total Equity Gross Minority Interest
35.27
+100.44%
17.60
-52.21%
36.83
-65.14%
105.65
Total Capitalization
35.27
+100.44%
17.60
-52.21%
36.83
-66.16%
108.81
Working Capital
88.75
+169.17%
32.97
+2.50%
32.17
-68.88%
103.38
Invested Capital
35.27
+100.44%
17.60
-56.16%
40.14
-65.24%
115.48
Total Debt
6.95
-14.59%
8.14
-34.88%
12.50
-37.29%
19.94
Capital Lease Obligations
6.95
-14.59%
8.14
-11.39%
9.19
-9.08%
10.11
Net Tangible Assets
35.27
+100.44%
17.60
-52.21%
36.83
-65.14%
105.65
Tangible Book Value
35.27
+100.44%
17.60
-52.21%
36.83
-65.14%
105.65
Derivative Product Liabilities
29.56
0.00
—
—
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
-4.99
+72.84%
-18.38
+73.22%
-68.62
+9.38%
-75.72
Cash Flow From Continuing Operating Activities
-4.99
+72.84%
-18.38
+73.22%
-68.62
+9.38%
-75.72
Net Income From Continuing Operations
-35.04
+39.84%
-58.24
+23.77%
-76.40
+13.40%
-88.22
Depreciation Amortization Depletion
1.54
-6.27%
1.64
-13.47%
1.90
+2.87%
1.85
Depreciation And Amortization
1.54
-6.27%
1.64
-13.47%
1.90
+2.87%
1.85
Other Non Cash Items
—
—
0.16
-29.60%
0.22
Stock Based Compensation
6.94
+7.85%
6.43
-12.84%
7.38
-12.37%
8.42
Operating Gains Losses
-3.56
-118800.00%
0.00
+0.00%
0.00
+200.00%
0.00
Gain Loss On Investment Securities
-3.56
—
—
—
Gain Loss On Sale Of PPE
0.00
-100.00%
0.00
+0.00%
0.00
+200.00%
0.00
Change In Working Capital
25.12
-20.95%
31.78
+2016.89%
-1.66
-182.73%
2.00
Change In Receivables
-5.00
0.00
—
—
Change In Prepaid Assets
3.08
+413.46%
-0.98
-242.59%
0.69
+100.00%
0.34
Change In Payables And Accrued Expense
-0.83
-4764.71%
-0.02
+99.10%
-1.89
-191.21%
2.07
Change In Accrued Expense
-0.98
+36.55%
-1.54
-981.71%
0.17
-88.96%
1.58
Change In Payable
0.15
-90.04%
1.53
+173.97%
-2.06
-525.36%
0.48
Change In Account Payable
0.15
-90.04%
1.53
+173.97%
-2.06
-525.36%
0.48
Change In Other Working Capital
27.88
-14.96%
32.78
—
—
Change In Other Current Assets
—
0.54
+17.17%
0.46
+17.65%
0.39
Change In Other Current Liabilities
—
-1.05
-14.05%
-0.92
-14.61%
-0.80
Investing Cash Flow
-0.52
-1338.89%
-0.04
+92.59%
-0.49
+73.97%
-1.87
Cash Flow From Continuing Investing Activities
-0.52
-1338.89%
-0.04
+92.59%
-0.49
+73.97%
-1.87
Net PPE Purchase And Sale
-0.52
-1338.89%
-0.04
+92.59%
-0.49
+73.97%
-1.87
Purchase Of PPE
-0.52
-1338.89%
-0.04
+92.59%
-0.49
+73.97%
-1.87
Capital Expenditure
-0.52
-1338.89%
-0.04
+92.59%
-0.49
+73.97%
-1.87
Financing Cash Flow
87.78
+200.64%
29.20
+545.74%
-6.55
-9392.75%
-0.07
Cash Flow From Continuing Financing Activities
87.78
+200.64%
29.20
+545.74%
-6.55
-9392.75%
-0.07
Net Issuance Payments Of Debt
0.00
+100.00%
-3.38
+49.91%
-6.75
-7843.53%
-0.09
Issuance Of Debt
—
—
—
0.00
Repayment Of Debt
0.00
+100.00%
-3.38
+49.91%
-6.75
-7843.53%
-0.09
Long Term Debt Issuance
—
—
—
0.00
Long Term Debt Payments
0.00
+100.00%
-3.38
+49.91%
-6.75
-7843.53%
-0.09
Net Long Term Debt Issuance
0.00
+100.00%
-3.38
+49.91%
-6.75
-7843.53%
-0.09
Net Common Stock Issuance
40.66
+495.68%
6.83
0.00
0.00
Proceeds From Stock Option Exercised
47.12
+82.97%
25.75
+12649.01%
0.20
+1162.50%
0.02
Net Other Financing Charges
—
—
—
—
Changes In Cash
82.27
+662.98%
10.78
+114.25%
-75.66
+2.58%
-77.66
Beginning Cash Position
57.07
+23.29%
46.29
-62.04%
121.95
-38.91%
199.61
End Cash Position
139.34
+144.14%
57.07
+23.29%
46.29
-62.04%
121.95
Free Cash Flow
-5.51
+70.08%
-18.41
+73.35%
-69.11
+10.93%
-77.59
Interest Paid Supplemental Data
0.00
-100.00%
0.06
-89.18%
0.57
+3.24%
0.56
Common Stock Issuance
40.66
+495.68%
6.83
0.00
0.00
Issuance Of Capital Stock
40.66
+495.68%
6.83
0.00
0.00
Net Preferred Stock Issuance
—
—
—
0.00
Preferred Stock Issuance
—
—
—
0.00
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category